(bright music)
-: We need to start getting our manufacturing processes
together from early on.
And I think that makes sense for gene therapies
because gene therapies are not small molecules.
There is some scientific basis that makes you think
that there's a higher probability than average of success
that you'll end up at the end of the process
with something that works.
So, as opposed to small molecules,
the goal always was your first batches-
you just want to save them.
You didn't want to spend a lot of money
because you knew that there was this pretty small chance
that those initial development lots
were going to end up never needing
to turn into production processes.
And so with gene therapies,
it may be that it goes back to having things right
from the beginning.
If we had essentially a cookbook for how you do things
early on so that they transfer to later on,
that might really help us move things forward.
And so I think they kind of have a connection
between what we learned in COVID-19
and this issue of what we can do to help
the technology transfer.